Gerresheimer AG

Gerresheimer is a holding company. Through its subsidiaries, Co. manufactures glass and plastic products for the pharma and healthcare industry. Co.'s operates in three divisions: Plastics & Devices, which its product portfolio includes products for the administration of medicines, such as insulin pens, inhalers, and prefillable syringes; Primary Packaging Glass, which produces glass primary packaging for medicines and cosmetics, such as pharma jars, ampoules, injection vials, cartridges, perfume flacons, and cream jars; and Life Science Research, which produces laboratory glassware for research, development, and analytics, such as beakers, Erlenmeyer flasks, and measuring cylinders.
  • TickerA0LD6E
  • ISINDE000A0LD6E6
  • SectorHealth Care Equipment & Services
  • CountryGermany

Analysts

GERRESHEIMER AG increases its risk exposure and slightly lowers to Neutral

GERRESHEIMER AG (DE), a company active in the Medical Equipment industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 2 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date May 31, 2019, the closing price was EUR 63.50 and its expected value was estimated at EUR 67.58.

Expert Corporate Governance Service (ECGS)

Gerresheimer - AGM 06 June 2019

General: Gerresheimer is a leading global partner to the pharma and healthcare industries. The Company's product portfolio includes pharmaceutical packaging and products for the administration of medicines: insulin pens, inhalers, micro pumps, prefillable syringes, injection vials, ampoules, bottles and containers for liquid and solid medicines with closure and safety systems as well as packaging for the cosmetics industry. Its international business is split into three divisions: Plastics & Devices, Primary Packaging Glass and Advanced Technologies. As of 24 April 2019, NN Group N.V. and Sti...

1 director bought

A director at Gerresheimer Group bought 1,450 shares at 67.410EUR and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of ...

Thomas J. Schiessle

Gerresheimer s Q1/19 außerordentlich - neuer Vorstand sehr optimistisch

Das Q1/19 lieferte eine erfreuliche Umsatz- und EBITDA-Expansion und guten Fortschritt bei den Wachstumsinitiativen. Auch ohne FX-Effekte und Einmaleinflüsse stiegt der EBITDA auf € 53,2 Mio. (+1,5 % ggü. Vj.).  Wie erwartet, prägte und verzerrte der Sensile-Einmaleffekt i.H.v. €+ 92,3 Mio. den Q1/19-Abschluß. Der Vorstand ist für Gj. 2019 sehr optimistisch, zumal einige Projektanläufe noch bevorstehen.

Thomas J. Schiessle

Gerresheimer s Q1/19 außerordentlich - neuer Vorstand sehr optimistisch

Das Q1/19 lieferte eine erfreuliche Umsatz- und EBITDA-Expansion und guten Fortschritt bei den Wachstumsinitiativen. Auch ohne FX-Effekte und Einmaleinflüsse stiegt der EBITDA auf € 53,2 Mio. (+1,5 % ggü. Vj.).  Wie erwartet, prägte und verzerrte der Sensile-Einmaleffekt i.H.v. €+ 92,3 Mio. den Q1/19-Abschluß. Der Vorstand ist für Gj. 2019 sehr optimistisch, zumal einige Projektanläufe noch bevorstehen.

Gerresheimer AG: Update following Q1 2018 trading

Detailed rationale for Gerresheimer's rating highlighting the slower than expected deleveraging profile due to a weak operating performance and difficult trading conditions.

Gerresheimer AG - November 2017 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Gerresheimer AG - August 2017 (LTM): Peer Snapshot

Peer Snapshot:  Gerresheimer AG - August 2017 (LTM) 16 November 2017 (in US millions) FYE Nov-15 FYE Nov-16 LTM Aug-17 FYE Dec-15 FYE Dec-16 LTM Sep-17 FYE Dec-15 FYE Dec-16 LTM Sep-17

Gerresheimer AG - May 2017 (LTM): Peer Snapshot

Peer Snapshot:  Gerresheimer AG - May 2017 (LTM) 16 August 2017 (in US millions) FYE Nov-15 FYE Nov-16 LTM May-17 FYE Dec-15 FYE Dec-16 LTM Mar-17 FYE Dec-15 FYE Dec-16 LTM Mar-17

Gerresheimer AG: Update to Discussion of Key Credit Factors

CORPORATES CREDIT OPINION 23 June 2017 Update RATINGS Gerresheimer AG Domicile Duesseldorf-Ger, Germany Long Term Rating Baa3 Type LT Issuer Rating - Fgn Curr Outlook Negative Please see the ratings section at the end of this report for more information. The ratings and outlook shown reflect information as of the publication date. Contacts Martin Chamberlain 44-20-7772-5213 VP-Senior Analyst marti

Thomas J. Schiessle

Gerresheimer s Q1/19 außerordentlich - neuer Vorstand sehr optimistisch

Das Q1/19 lieferte eine erfreuliche Umsatz- und EBITDA-Expansion und guten Fortschritt bei den Wachstumsinitiativen. Auch ohne FX-Effekte und Einmaleinflüsse stiegt der EBITDA auf € 53,2 Mio. (+1,5 % ggü. Vj.).  Wie erwartet, prägte und verzerrte der Sensile-Einmaleffekt i.H.v. €+ 92,3 Mio. den Q1/19-Abschluß. Der Vorstand ist für Gj. 2019 sehr optimistisch, zumal einige Projektanläufe noch bevorstehen.

Thomas J. Schiessle

Gerresheimer s Q1/19 außerordentlich - neuer Vorstand sehr optimistisch

Das Q1/19 lieferte eine erfreuliche Umsatz- und EBITDA-Expansion und guten Fortschritt bei den Wachstumsinitiativen. Auch ohne FX-Effekte und Einmaleinflüsse stiegt der EBITDA auf € 53,2 Mio. (+1,5 % ggü. Vj.).  Wie erwartet, prägte und verzerrte der Sensile-Einmaleffekt i.H.v. €+ 92,3 Mio. den Q1/19-Abschluß. Der Vorstand ist für Gj. 2019 sehr optimistisch, zumal einige Projektanläufe noch bevorstehen.

Thomas J. Schiessle

2019ff - zurück zum Wachstum – neuer Vorstand mit Elan

Das H2/18 lieferte das von uns erwartete und nötigte anziehende Wachstum, so dass die (FX-bereinigte) Guidance - „Umsatz zwischen € 1,38 – 1,4 Mrd.… adj. EBITDA eher bei rund € 305 Mio.“ - erreicht werden konnte. Das Marktwachstum ist also zurück und sollte auch 2019ff anhalten. Dietmar Siemssen hatte ab 01.11.18 den CEO-Posten übernommen. Spätestens zum 01.07.19 übernimmt Dr. Bernd Metzner den CFO-Posten. Die Investoren honorieren die bestätigten Wachstumsperspektiven. Wegen Einmaleffekt i.H.v. €+ 90 Mio. dürfte das Q1/19 sehr stark werden. Unsere Schätzreihe hat Bestand, denn die am 14.02.1...

Thomas J. Schiessle

Wie erwartet: Q3 – Vorstandsdemission: unerwartet

Wie erwartet, zeigt das Q3 bzw. das H2/18 eine Dynamikbeschleunigung; so dass die (FX-bereinigte) Guidance für das laufende Geschäftsjahr - erreicht werden könnte. Organisch stieg der Konzern-Umsatz um 3,5 %, das Marktwachstum ist also zurück. 

Zafer Rüzgar

GERRESHEIMER AG - Reported earnings missed expectations – Adj. EBITDA now more at the lower end of the guidance range expected

1 director bought

A director at Gerresheimer Group bought 1,450 shares at 67.410EUR and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of ...

GERRESHEIMER AG increases its risk exposure and slightly lowers to Neutral

GERRESHEIMER AG (DE), a company active in the Medical Equipment industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 2 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date May 31, 2019, the closing price was EUR 63.50 and its expected value was estimated at EUR 67.58.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

MarketLine Department

Zignago Vetro SpA - Strategy, SWOT and Corporate Finance Report

Zignago Vetro SpA - Strategy, SWOT and Corporate Finance Report Summary Zignago Vetro SpA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Zignago Vetro SpA (Zignago Vetro), a subsidiary of Zignago Holding S.p.A is a manufacturer and supplier of hallow glass containers. The company principally produces glass containers for cosmetics and perfumery, food and bever...

MarketLine Department

Vidrala S.A. - Strategy, SWOT and Corporate Finance Report

Vidrala S.A. - Strategy, SWOT and Corporate Finance Report Summary Vidrala S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Vidrala S.A. (Vidrala) is a glass packaging products manufacturer in Spain. The company produces, distributes and sells a wide range of glass bottles and containers. The company caters its products to the food and beverage industry to ...

MarketLine Department

Ardagh Group SA - Strategy, SWOT and Corporate Finance Report

Ardagh Group SA - Strategy, SWOT and Corporate Finance Report Summary Ardagh Group SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Ardagh Group S.A. (Ardagh) is a provider of packaging solutions. The company primarily produces and markets a wide range of glass and metal packaging products such as tinplate and aluminum packaging products that include two- and...

Expert Corporate Governance Service (ECGS)

Gerresheimer - AGM 06 June 2019

General: Gerresheimer is a leading global partner to the pharma and healthcare industries. The Company's product portfolio includes pharmaceutical packaging and products for the administration of medicines: insulin pens, inhalers, micro pumps, prefillable syringes, injection vials, ampoules, bottles and containers for liquid and solid medicines with closure and safety systems as well as packaging for the cosmetics industry. Its international business is split into three divisions: Plastics & Devices, Primary Packaging Glass and Advanced Technologies. As of 24 April 2019, NN Group N.V. and Sti...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch